Iteru’s Solution

Proof of Concept Platform

Iteru has completed a proof of concept platform to validate its core concepts leading to.

  • Building accurate proprietary AI algorithms.
  • Improve the quality of biomedical data.
  • Attain scalability of 1 petabyte.
  • Integrate all non-multimodal and multimodal, in a single data lake.
  • Implement classification algorithms providing automated data labeling to isolate data related to analysis. 

In addition to drug discovery, because the platform’s scalability and ability to access all data types, it provides a paradigm for pharma to digitize application such as patient care, document management and security.

AI Data Analysis

The proof of concept platform applies AI (NLP) and proprietary algorithms to determine the association of cancer with biological entities. Dimensionality is reduced to visualize results in 3-D. It allows a researcher to expedite drug discovery by identifying new targets, investigating toxicity, efficacy, drug repurposing and different aspects of pharma R&D. Interactive tools allow the researcher to tune parameters that impact the results, enabling him/her to gain more understanding of the disease and obtain actionable results. Examples of data analysis are provided below.

The Wide Scope of the Platform

The biggest impediments to drug discovery, pharma digitization and other aspects of pharma R&D are: scalability, difficulty of integrating non-multimodal and multimodal data, lack of effective data cleansing and inaccessibility of data stored in silos. These are formidable problems for which only partial solutions exist. Iteru provides an elegant and complete solution. The product is scalable to 1 petabyte. The figure below shows a rudimentary block diagram of the platform. Starting at the left-hand side, biomedical data, both multimodal and non-multimodal is integrated into a data lake, labelled and preprocessed.

A block diagram of Iteru’s Platform

In addition to drug discovery and therapeutics, the platform can be used to address other aspects of pharma digitization, such as, clinical development, data governance, data analysis, patient care, document management and enhancement of data security. To address other aspects of pharma digitization, there is need to ingest more data types. Currently the platform extracts document’s attributes such as permissions, ownership, date and time data accessed. Such information is usable by customer’s security & compliance software.